Almitrine Bismesylate + Raubasine

Welcome to Dwaey, specifically on Almitrine Bismesylate + Raubasine page.
This medicine contains important and useful components, as it consists of
Almitrine Bismesylate + Raubasine is available in the market in concentration.

Generic Name of Almitrine Bismesylate + Raubasine - Learn More

Almitrine Bismesylate + Raubasine

Almitrine Bismesylate + Raubasine Precaution - What You Need to Know

- Contraindications: Almitrine Bismesylate + Raubasine is contraindicated in patients with hypersensitivity to either of the components. It should not be used concurrently with other medications containing almitrine or with monoamine oxidase inhibitors (MAOIs).
- Peripheral Neuropathy: Almitrine bismesylate has been associated with sensory peripheral neuropathy, which can occur between 9 and 25 months after starting treatment. Regular monitoring for symptoms of neuropathy, such as numbness, tingling, or weakness in the extremities, is essential.
- Cardiovascular Effects: Due to its vasodilatory effects, raubasine can cause hypotension, especially in patients with pre-existing cardiovascular conditions. Monitor blood pressure regularly during treatment.
- Respiratory Stimulation: Almitrine is a respiratory stimulant that can increase respiratory drive, which may not be suitable for patients with certain types of respiratory failure, such as those with severe chronic obstructive pulmonary disease (COPD) who are at risk of hypercapnia.
- Elderly Patients: Special caution is advised when using this combination in elderly patients due to the increased risk of adverse effects, including neurological and cardiovascular events. Regular monitoring of elderly patients is recommended.
- Pregnancy and Breastfeeding: The safety of Almitrine Bismesylate + Raubasine during pregnancy and breastfeeding has not been established. It should be used only if the potential benefits outweigh the risks. Consultation with a healthcare provider is essential before use.
- Drug Interactions: This combination should not be used with other medications containing almitrine or with MAOIs. It may also interact with other vasodilators, antihypertensive drugs, and medications that affect the central nervous system. Always inform your doctor about all medications you are taking.
- Hepatic and Renal Impairment: Patients with liver or kidney disease should use this combination with caution, as both almitrine and raubasine are metabolized by the liver and excreted through the kidneys. Dose adjustments may be necessary for these patients.
- Neurological Effects: The combination of almitrine and raubasine can affect the central nervous system, potentially causing dizziness, headache, and other neurological symptoms. Patients should avoid activities that require mental alertness, such as driving or operating machinery, until they know how the medication affects them.
- Monitoring: Regular medical monitoring, including blood pressure checks, liver function tests, and neurological assessments, is essential while taking Almitrine Bismesylate + Raubasine. This helps to detect and manage any potential adverse effects early.

Almitrine Bismesylate + Raubasine Indication - Uses and Benefits

- Chronic Obstructive Pulmonary Disease (COPD): Almitrine Bismesylate + Raubasine is used to improve respiratory function in patients with COPD by stimulating respiration and enhancing oxygenation.
- Chronic Hypoxemia: The combination is indicated for the treatment of chronic hypoxemia, a condition characterized by low oxygen levels in the blood, by improving oxygen saturation.
- Hypertension: Raubasine, a component of this combination, is used to manage hypertension due to its vasodilatory effects, which help to lower blood pressure.
- Stroke Rehabilitation: Almitrine Bismesylate + Raubasine is used to accelerate recovery and reduce neurological damage after a stroke. It improves cerebral blood flow and oxygenation, aiding in functional rehabilitation.
- Age-Related Cerebral Disorders: The combination is used to treat age-related cerebral disorders, including minor neurological disorders and cognitive decline, by improving cerebral circulation and oxygenation.
- Visual Disorders: Almitrine Bismesylate + Raubasine is indicated for visual disorders related to age and circulation, such as macular degeneration and retinopathy, by enhancing blood flow to the eyes.
- Inner Ear Disorders: The medication is used to treat disorders of the inner ear, including hearing loss, dizziness, and tinnitus, by improving blood flow and reducing symptoms.
- Cerebrovascular Diseases: The combination is used to manage various cerebrovascular diseases, including ischemic conditions that affect blood flow to the brain, by improving circulation and oxygenation.
- Functional Rehabilitation: Almitrine Bismesylate + Raubasine is used to support functional rehabilitation after neurological events, such as stroke, by enhancing cerebral blood flow and oxygenation, which aids in recovery.
- Respiratory Stimulation: Almitrine acts as a respiratory stimulant, enhancing respiration by acting on peripheral chemoreceptors. This is particularly beneficial in conditions where respiratory drive is compromised, such as in certain types of respiratory failure.

Almitrine Bismesylate + Raubasine Contraindications - Important Warnings

- Hypersensitivity: Almitrine Bismesylate + Raubasine is contraindicated in patients with a known hypersensitivity to either almitrine or raubasine. Allergic reactions can manifest as skin rashes, itching, or difficulty breathing.
- Concurrent Use with MAOIs: The combination should not be used concurrently with monoamine oxidase inhibitors (MAOIs) due to the risk of severe drug interactions, including hypertensive crisis.
- Severe Liver Disease: Patients with severe liver disease should avoid this combination, as both almitrine and raubasine are metabolized by the liver. Impaired liver function can lead to increased drug levels and toxicity.
- Severe Renal Impairment: The combination is contraindicated in patients with severe renal impairment, as the drugs are excreted through the kidneys. Impaired renal function can lead to drug accumulation and increased side effects.
- Severe Cardiovascular Disease: Patients with severe cardiovascular disease, including uncontrolled hypertension or recent heart attacks, should avoid this combination due to the risk of exacerbating cardiovascular conditions.
- Severe Respiratory Failure: The combination is contraindicated in patients with severe respiratory failure, particularly those at risk of hypercapnia, as almitrine can increase respiratory drive and worsen the condition.
- Pregnancy and Breastfeeding: The safety of Almitrine Bismesylate + Raubasine during pregnancy and breastfeeding has not been established. It should be avoided unless the potential benefits outweigh the risks. Consultation with a healthcare provider is essential before use.
- Concurrent Use with Other Almitrine-Containing Medications: The combination should not be used with other medications containing almitrine, as this can lead to increased drug levels and toxicity.
- Severe Neurological Disorders: Patients with severe neurological disorders, including seizures or severe cognitive impairment, should avoid this combination due to the risk of exacerbating neurological symptoms.
- Severe Psychiatric Disorders: The combination is contraindicated in patients with severe psychiatric disorders, including schizophrenia or severe depression, due to the risk of exacerbating psychiatric symptoms.

Almitrine Bismesylate + Raubasine Side Effects - What to Expect

- Peripheral Neuropathy: Almitrine bismesylate has been associated with sensory peripheral neuropathy, which can occur between 9 and 25 months after starting treatment. Symptoms include numbness, tingling, or weakness in the extremities.
- Cardiovascular Effects: Raubasine can cause hypotension, especially in patients with pre-existing cardiovascular conditions. Symptoms include dizziness, lightheadedness, and fainting.
- Respiratory Stimulation: Almitrine can increase respiratory drive, which may not be suitable for patients with certain types of respiratory failure, such as those at risk of hypercapnia. Symptoms include shortness of breath and increased respiratory rate.
- Neurological Effects: The combination of almitrine and raubasine can cause neurological side effects, including dizziness, headache, and confusion. These effects can be more pronounced in elderly patients.
- Gastrointestinal Effects: Almitrine Bismesylate + Raubasine can cause gastrointestinal side effects, including nausea, vomiting, and abdominal pain. These symptoms are usually mild to moderate and may resolve over time.
- Hepatic Effects: The combination can affect liver function, leading to abnormal liver enzyme levels. Regular liver function tests are essential while taking this medication.
- Renal Effects: Almitrine Bismesylate + Raubasine can affect kidney function, leading to abnormal kidney function tests. Regular monitoring of kidney function is essential while taking this medication.
- Allergic Reactions: Allergic reactions to Almitrine Bismesylate + Raubasine can occur, manifesting as skin rashes, itching, or difficulty breathing. Seek immediate medical attention if you experience these symptoms.
- Psychiatric Effects: The combination can cause psychiatric side effects, including anxiety, depression, and hallucinations. These effects can be more pronounced in patients with pre-existing psychiatric conditions.
- Visual Disturbances: Almitrine Bismesylate + Raubasine can cause visual disturbances, including blurred vision and changes in visual acuity. Regular eye examinations are essential while taking this medication.

Almitrine Bismesylate + Raubasine Mode of Action - How It Works

- Respiratory Stimulation: Almitrine acts as a respiratory stimulant by enhancing respiration through its action on peripheral chemoreceptors located on the carotid bodies. This increases arterial oxygen tension and decreases arterial carbon dioxide tension, improving oxygenation in patients with chronic obstructive pulmonary disease (COPD).
- Vasodilation: Raubasine acts as a vasodilator, relaxing blood vessels and improving blood flow. This effect is particularly beneficial in conditions where blood flow is compromised, such as in cerebrovascular diseases and hypertension.
- Adrenolytic Activity: Raubasine has adrenolytic activity, which is predominantly related to a post-synaptic blocking effect. This helps to reduce sympathetic nervous system activity, contributing to its vasodilatory effects.
- Cerebral Blood Flow: The combination of almitrine and raubasine improves cerebral blood flow and oxygenation, which is beneficial in conditions such as stroke rehabilitation and age-related cerebral disorders. This enhances the delivery of oxygen and nutrients to the brain, aiding in functional recovery.
- Peripheral Chemoreceptor Stimulation: Almitrine stimulates peripheral chemoreceptors, which are sensitive to changes in oxygen and carbon dioxide levels in the blood. This stimulation enhances respiratory drive, improving ventilation and oxygenation in patients with respiratory disorders.
- Neuroprotective Effects: The combination has neuroprotective effects, reducing neurological damage and accelerating recovery after stroke. This is achieved through improved cerebral blood flow and oxygenation, which supports the healing of damaged neurons.
- Anti-Ischemic Effects: Almitrine Bismesylate + Raubasine has anti-ischemic effects, improving blood flow to ischemic tissues, such as in visual disorders related to circulation and inner ear disorders. This enhances the delivery of oxygen and nutrients to affected tissues, reducing symptoms.
- Central Nervous System (CNS) Effects: The combination affects the central nervous system, potentially causing neurological side effects such as dizziness and headache. These effects are thought to be related to the drug's action on neurotransmitter systems in the brain.
- Hormonal Effects: Almitrine Bismesylate + Raubasine can affect hormonal systems, including the release of stress hormones such as cortisol. This can contribute to its effects on respiratory stimulation and cerebral blood flow.
- Metabolic Effects: The combination can affect metabolic processes, including the metabolism of lipids and glucose. This can contribute to its effects on blood pressure and cerebral blood flow.

Almitrine Bismesylate + Raubasine Drug Interactions - What to Avoid

- MAO Inhibitors (MAOIs): Almitrine Bismesylate + Raubasine should not be used concurrently with monoamine oxidase inhibitors (MAOIs) due to the risk of severe drug interactions, including hypertensive crisis.
- Other Almitrine-Containing Medications: The combination should not be used with other medications containing almitrine, as this can lead to increased drug levels and toxicity.
- Antihypertensive Drugs: Raubasine, a vasodilator, can interact with antihypertensive drugs, potentially enhancing their effects and leading to hypotension. Dose adjustments may be necessary when used together.
- Central Nervous System (CNS) Depressants: Almitrine Bismesylate + Raubasine can interact with CNS depressants, including sedatives, hypnotics, and anxiolytics, potentially enhancing their effects and leading to increased sedation and dizziness.
- Anticoagulants: The combination can interact with anticoagulants, such as warfarin, potentially affecting blood clotting. Close monitoring of coagulation parameters is essential when these medications are used together.
- Antidiabetic Drugs: Almitrine Bismesylate + Raubasine can interact with antidiabetic drugs, potentially affecting blood sugar levels. Close monitoring of blood sugar levels is essential when these medications are used together.
- Anticonvulsants: The combination can interact with anticonvulsants, potentially affecting their effectiveness or increasing the risk of seizures. Dose adjustments may be necessary when used together.
- Antipsychotics: Almitrine Bismesylate + Raubasine can interact with antipsychotics, potentially enhancing their effects and leading to increased sedation and other neurological side effects.
- Antidepressants: The combination can interact with antidepressants, potentially enhancing their effects and leading to increased neurological side effects, such as dizziness and headache.
- Alcohol: Alcohol can interact with Almitrine Bismesylate + Raubasine, potentially enhancing its effects and leading to increased sedation and dizziness. Avoid alcohol consumption while taking this medication.

Almitrine Bismesylate + Raubasine Adult Dose - Recommended Dosage

- Chronic Obstructive Pulmonary Disease (COPD): The usual dose for adults with COPD is 50 mg to 100 mg of almitrine bismesylate per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.
- Chronic Hypoxemia: For the treatment of chronic hypoxemia, the typical dose is 50 mg to 100 mg of almitrine bismesylate per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.
- Hypertension: The usual dose for managing hypertension with raubasine is 10 mg to 20 mg per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.
- Stroke Rehabilitation: For accelerating recovery and reducing neurological damage after a stroke, the typical dose is 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Age-Related Cerebral Disorders: The usual dose for treating age-related cerebral disorders is 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Visual Disorders: For visual disorders related to age and circulation, the typical dose is 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Inner Ear Disorders: For disorders of the inner ear, including hearing loss, dizziness, and tinnitus, the usual dose is 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Cerebrovascular Diseases: For managing various cerebrovascular diseases, the typical dose is 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Functional Rehabilitation: For supporting functional rehabilitation after neurological events, the usual dose is 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Respiratory Stimulation: For conditions where respiratory drive is compromised, the typical dose is 50 mg to 100 mg of almitrine bismesylate per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.

Almitrine Bismesylate + Raubasine Child Dose - Dosage for Children

- Chronic Obstructive Pulmonary Disease (COPD): The usual dose for children with COPD is 25 mg to 50 mg of almitrine bismesylate per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.
- Chronic Hypoxemia: For the treatment of chronic hypoxemia in children, the typical dose is 25 mg to 50 mg of almitrine bismesylate per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.
- Hypertension: The usual dose for managing hypertension in children with raubasine is 5 mg to 10 mg per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.
- Stroke Rehabilitation: For accelerating recovery and reducing neurological damage after a stroke in children, the typical dose is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Age-Related Cerebral Disorders: The usual dose for treating age-related cerebral disorders in children is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Visual Disorders: For visual disorders related to age and circulation in children, the typical dose is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Inner Ear Disorders: For disorders of the inner ear in children, including hearing loss, dizziness, and tinnitus, the usual dose is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Cerebrovascular Diseases: For managing various cerebrovascular diseases in children, the typical dose is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Functional Rehabilitation: For supporting functional rehabilitation after neurological events in children, the usual dose is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken twice daily. The dose may be adjusted based on individual response and tolerance.
- Respiratory Stimulation: For conditions where respiratory drive is compromised in children, the typical dose is 25 mg to 50 mg of almitrine bismesylate per day, divided into two doses. The dose may be adjusted based on individual response and tolerance.

Almitrine Bismesylate + Raubasine Renal Dose - Dosage for Kidney Conditions

- Mild to Moderate Renal Impairment: For patients with mild to moderate renal impairment (creatinine clearance 30-50 mL/min), the starting dose of Almitrine Bismesylate + Raubasine should be reduced to 30 mg of almitrine bismesylate plus 10 mg of raubasine, taken once daily. The dose may be adjusted based on individual response and tolerance.
- Severe Renal Impairment: In patients with severe renal impairment (creatinine clearance less than 30 mL/min), the combination should be used with caution, and the starting dose should be further reduced. The typical starting dose is 15 mg of almitrine bismesylate plus 5 mg of raubasine, taken once daily. The dose may be adjusted based on individual response and tolerance.
- End-Stage Renal Disease: Almitrine Bismesylate + Raubasine is generally not recommended for patients with end-stage renal disease (creatinine clearance less than 10 mL/min) due to the risk of accumulation and increased side effects. If use is necessary, close monitoring and further dose reduction may be required.
- Dialysis: There is limited information on the use of Almitrine Bismesylate + Raubasine in patients undergoing dialysis. If the combination is used in these patients, close monitoring and individualized dosing are essential to avoid adverse effects.
- Monitoring: Regular monitoring of renal function is important in patients with renal impairment who are taking Almitrine Bismesylate + Raubasine. Dose adjustments should be made based on changes in renal function and individual response to the medication.
- Dose Adjustments: Dose adjustments may be necessary based on individual response and tolerance. It is important to follow the prescribing healthcare provider's instructions for dose adjustments. In some cases, a lower starting dose may be recommended for patients with certain medical conditions.
- Special Considerations: Patients with renal impairment may be more sensitive to the effects of Almitrine Bismesylate + Raubasine, particularly fluid retention and electrolyte imbalances. Close monitoring of fluid status and electrolyte levels is essential.
- Concomitant Medications: Patients with renal impairment may be taking other medications that can interact with Almitrine Bismesylate + Raubasine. It is important to inform your doctor about all medications you are taking to avoid potential drug interactions.
- Hydration: Adequate hydration is essential for patients with renal impairment who are taking Almitrine Bismesylate + Raubasine. Dehydration can exacerbate renal function and increase the risk of side effects. Regular fluid intake is recommended.
- Regular Check-Ups: Regular medical check-ups are essential while taking Almitrine Bismesylate + Raubasine to monitor for side effects and ensure the medication is working as intended. This includes blood tests and physical examinations.